Entellus Medical, Inc. (ENTL) Earns “Hold” Rating from Canaccord Genuity
Entellus Medical, Inc. (NASDAQ:ENTL)‘s stock had its “hold” rating restated by analysts at Canaccord Genuity in a research note issued on Tuesday. They currently have a $17.00 price objective on the medical technology company’s stock. Canaccord Genuity’s price objective would indicate a potential downside of 9.43% from the stock’s previous close.
Other equities analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reissued a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Finally, Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.86.
Shares of Entellus Medical (NASDAQ ENTL) traded up 0.16% on Tuesday, reaching $18.77. 66,011 shares of the company’s stock were exchanged. The company’s market capitalization is $476.21 million. The stock’s 50-day moving average price is $18.29 and its 200-day moving average price is $18.29. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.69.
Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. During the same period in the prior year, the business posted ($0.27) EPS. The business’s revenue was up 18.0% on a year-over-year basis. Analysts anticipate that Entellus Medical will post ($1.61) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/17/entellus-medical-inc-entl-earns-hold-rating-from-canaccord-genuity.html.
In other news, VP Timothy B. Petrick sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total value of $40,020.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian E. Farley sold 3,972 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $19.10, for a total transaction of $75,865.20. The disclosure for this sale can be found here. Insiders sold a total of 79,650 shares of company stock valued at $1,510,252 in the last three months. Insiders own 7.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTL. Wells Fargo & Company MN increased its position in shares of Entellus Medical by 7.2% in the 4th quarter. Wells Fargo & Company MN now owns 464,550 shares of the medical technology company’s stock worth $7,832,000 after purchasing an additional 31,082 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Entellus Medical by 165.4% in the 4th quarter. Ameriprise Financial Inc. now owns 140,925 shares of the medical technology company’s stock valued at $2,376,000 after buying an additional 87,825 shares during the period. Federated Investors Inc. PA boosted its holdings in shares of Entellus Medical by 78.5% in the 4th quarter. Federated Investors Inc. PA now owns 103,100 shares of the medical technology company’s stock valued at $1,738,000 after buying an additional 45,343 shares during the period. First Light Asset Management LLC boosted its holdings in shares of Entellus Medical by 61.4% in the 4th quarter. First Light Asset Management LLC now owns 391,497 shares of the medical technology company’s stock valued at $6,601,000 after buying an additional 148,965 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Entellus Medical by 3.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 266,642 shares of the medical technology company’s stock valued at $4,496,000 after buying an additional 8,610 shares during the period. 70.27% of the stock is owned by institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.